The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Highlights
The global Attenuated Vaccine for Human Rabies market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
The major global manufacturers of Attenuated Vaccine for Human Rabies include AstraZeneca, GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, Cadila Pharmaceuticals Ltd, Novartis AG, Pfizer Inc, Liaoning Yisheng Biopharmaceutical Co., Ltd and Lanzhou Institute of Biological Products Co., Ltd, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Vero Cell, which accounted for % of the global market of Attenuated Vaccine for Human Rabies in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Attenuated Vaccine for Human Rabies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attenuated Vaccine for Human Rabies.
The Attenuated Vaccine for Human Rabies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Attenuated Vaccine for Human Rabies market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attenuated Vaccine for Human Rabies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Some of the prominent players reviewed in the research report include:
- AstraZeneca
- GlaxoSmithKline
- Merck & Co Inc
- Sanofi Pasteur, Inc
- Cadila Pharmaceuticals Ltd
- Novartis AG
- Pfizer Inc
- Liaoning Yisheng Biopharmaceutical Co., Ltd
- Lanzhou Institute of Biological Products Co., Ltd
- Changchun Zhuoyi Biological Co., Ltd
- Guangzhou Nuocheng Biological Products Co., Ltd
- Ningbo Rongan Biopharmaceutical Co., Ltd
- Shandong Yidu Biotechnology Co., Ltd
- Chengdu Kanghua Biological Products Co., Ltd
- Wuhan Institute of Biological Products Co., Ltd
Product Type Insights
Global markets are presented by Attenuated Vaccine for Human Rabies type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Attenuated Vaccine for Human Rabies are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Attenuated Vaccine for Human Rabies segment by Type
- Vero Cell
- Human Diploid Cell
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Attenuated Vaccine for Human Rabies market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Attenuated Vaccine for Human Rabies market.
Attenuated Vaccine for Human Rabies segment by Application
- Hospital
- Clinic
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina, Colombia)
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Attenuated Vaccine for Human Rabies market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market
- This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Attenuated Vaccine for Human Rabies industry.
- This report helps stakeholders to gain insights into which regions to target globally
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Attenuated Vaccine for Human Rabies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index
1 Attenuated Vaccine for Human Rabies Market Overview
1.1 Product Overview and Scope of Attenuated Vaccine for Human Rabies
1.2 Attenuated Vaccine for Human Rabies Segment by Type
1.2.1 Global Attenuated Vaccine for Human Rabies Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Vero Cell
1.2.3 Human Diploid Cell
1.3 Attenuated Vaccine for Human Rabies Segment by Application
1.3.1 Global Attenuated Vaccine for Human Rabies Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Attenuated Vaccine for Human Rabies Market Size Estimates and Forecasts
1.4.1 Global Attenuated Vaccine for Human Rabies Revenue 2017-2028
1.4.2 Global Attenuated Vaccine for Human Rabies Sales 2017-2028
1.4.3 Attenuated Vaccine for Human Rabies Market Size by Region: 2017 Versus 2021 Versus 2028
2 Attenuated Vaccine for Human Rabies Market Competition by Manufacturers
2.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2017-2022)
2.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Attenuated Vaccine for Human Rabies Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Attenuated Vaccine for Human Rabies Manufacturing Sites, Area Served, Product Type
2.5 Attenuated Vaccine for Human Rabies Market Competitive Situation and Trends
2.5.1 Attenuated Vaccine for Human Rabies Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Attenuated Vaccine for Human Rabies Players Market Share by Revenue
2.5.3 Global Attenuated Vaccine for Human Rabies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Attenuated Vaccine for Human Rabies Retrospective Market Scenario by Region
3.1 Global Attenuated Vaccine for Human Rabies Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Attenuated Vaccine for Human Rabies Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.3.1 North America Attenuated Vaccine for Human Rabies Sales by Country
3.3.2 North America Attenuated Vaccine for Human Rabies Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.4.1 Europe Attenuated Vaccine for Human Rabies Sales by Country
3.4.2 Europe Attenuated Vaccine for Human Rabies Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Attenuated Vaccine for Human Rabies Market Facts & Figures by Region
3.5.1 Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region
3.5.2 Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.6.1 Latin America Attenuated Vaccine for Human Rabies Sales by Country
3.6.2 Latin America Attenuated Vaccine for Human Rabies Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Attenuated Vaccine for Human Rabies Market Facts & Figures by Country
3.7.1 Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country
3.7.2 Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Attenuated Vaccine for Human Rabies Historic Market Analysis by Type
4.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
4.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Type (2017-2022)
4.3 Global Attenuated Vaccine for Human Rabies Price by Type (2017-2022)
5 Global Attenuated Vaccine for Human Rabies Historic Market Analysis by Application
5.1 Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
5.2 Global Attenuated Vaccine for Human Rabies Revenue Market Share by Application (2017-2022)
5.3 Global Attenuated Vaccine for Human Rabies Price by Application (2017-2022)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.1.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.2.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Merck & Co Inc
6.3.1 Merck & Co Inc Corporation Information
6.3.2 Merck & Co Inc Description and Business Overview
6.3.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.3.5 Merck & Co Inc Recent Developments/Updates
6.4 Sanofi Pasteur, Inc
6.4.1 Sanofi Pasteur, Inc Corporation Information
6.4.2 Sanofi Pasteur, Inc Description and Business Overview
6.4.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.4.5 Sanofi Pasteur, Inc Recent Developments/Updates
6.5 Cadila Pharmaceuticals Ltd
6.5.1 Cadila Pharmaceuticals Ltd Corporation Information
6.5.2 Cadila Pharmaceuticals Ltd Description and Business Overview
6.5.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.5.5 Cadila Pharmaceuticals Ltd Recent Developments/Updates
6.6 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
6.6.5 Novartis AG Recent Developments/Updates
6.7 Pfizer Inc
6.6.1 Pfizer Inc Corporation Information
6.6.2 Pfizer Inc Description and Business Overview
6.6.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
6.7.5 Pfizer Inc Recent Developments/Updates
6.8 Liaoning Yisheng Biopharmaceutical Co., Ltd
6.8.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Corporation Information
6.8.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Description and Business Overview
6.8.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments/Updates
6.9 Lanzhou Institute of Biological Products Co., Ltd
6.9.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
6.9.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
6.9.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.9.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
6.10 Changchun Zhuoyi Biological Co., Ltd
6.10.1 Changchun Zhuoyi Biological Co., Ltd Corporation Information
6.10.2 Changchun Zhuoyi Biological Co., Ltd Description and Business Overview
6.10.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.10.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments/Updates
6.11 Guangzhou Nuocheng Biological Products Co., Ltd
6.11.1 Guangzhou Nuocheng Biological Products Co., Ltd Corporation Information
6.11.2 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.11.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.11.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments/Updates
6.12 Ningbo Rongan Biopharmaceutical Co., Ltd
6.12.1 Ningbo Rongan Biopharmaceutical Co., Ltd Corporation Information
6.12.2 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.12.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.12.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments/Updates
6.13 Shandong Yidu Biotechnology Co., Ltd
6.13.1 Shandong Yidu Biotechnology Co., Ltd Corporation Information
6.13.2 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.13.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.13.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments/Updates
6.14 Chengdu Kanghua Biological Products Co., Ltd
6.14.1 Chengdu Kanghua Biological Products Co., Ltd Corporation Information
6.14.2 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.14.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.14.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments/Updates
6.15 Wuhan Institute of Biological Products Co., Ltd
6.15.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
6.15.2 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Description and Business Overview
6.15.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
6.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Attenuated Vaccine for Human Rabies Manufacturing Cost Analysis
7.1 Attenuated Vaccine for Human Rabies Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
7.4 Attenuated Vaccine for Human Rabies Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Attenuated Vaccine for Human Rabies Distributors List
8.3 Attenuated Vaccine for Human Rabies Customers
9 Attenuated Vaccine for Human Rabies Market Dynamics
9.1 Attenuated Vaccine for Human Rabies Industry Trends
9.2 Attenuated Vaccine for Human Rabies Market Drivers
9.3 Attenuated Vaccine for Human Rabies Market Challenges
9.4 Attenuated Vaccine for Human Rabies Market Restraints
10 Global Market Forecast
10.1 Attenuated Vaccine for Human Rabies Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Attenuated Vaccine for Human Rabies by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Attenuated Vaccine for Human Rabies by Type (2023-2028)
10.2 Attenuated Vaccine for Human Rabies Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Attenuated Vaccine for Human Rabies by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Attenuated Vaccine for Human Rabies by Application (2023-2028)
10.3 Attenuated Vaccine for Human Rabies Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Attenuated Vaccine for Human Rabies by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Attenuated Vaccine for Human Rabies by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Attenuated Vaccine for Human Rabies Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Attenuated Vaccine for Human Rabies Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Attenuated Vaccine for Human Rabies Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Attenuated Vaccine for Human Rabies Market Competitive Situation by Manufacturers in 2021
Table 5. Global Attenuated Vaccine for Human Rabies Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Attenuated Vaccine for Human Rabies Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Attenuated Vaccine for Human Rabies Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Attenuated Vaccine for Human Rabies Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Attenuated Vaccine for Human Rabies Manufacturing Sites and Area Served
Table 11. Manufacturers Attenuated Vaccine for Human Rabies Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Attenuated Vaccine for Human Rabies by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Attenuated Vaccine for Human Rabies as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Attenuated Vaccine for Human Rabies Sales by Region (2017-2022) & (K Units)
Table 16. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Table 17. Global Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2017-2022)
Table 19. North America Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 20. North America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 21. North America Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 23. Europe Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 24. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 25. Europe Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Attenuated Vaccine for Human Rabies Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Attenuated Vaccine for Human Rabies Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2017-2022)
Table 31. Latin America Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 33. Latin America Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Attenuated Vaccine for Human Rabies Revenue Market Share by Country (2017-2022)
Table 39. Global Attenuated Vaccine for Human Rabies Sales by Type (2017-2022) & (K Units)
Table 40. Global Attenuated Vaccine for Human Rabies Sales Market Share by Type (2017-2022)
Table 41. Global Attenuated Vaccine for Human Rabies Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Attenuated Vaccine for Human Rabies Revenue Share by Type (2017-2022)
Table 43. Global Attenuated Vaccine for Human Rabies Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Attenuated Vaccine for Human Rabies Sales (K Units) by Application (2017-2022)
Table 45. Global Attenuated Vaccine for Human Rabies Sales Market Share by Application (2017-2022)
Table 46. Global Attenuated Vaccine for Human Rabies Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Attenuated Vaccine for Human Rabies Revenue Share by Application (2017-2022)
Table 48. Global Attenuated Vaccine for Human Rabies Price by Application (2017-2022) & (US$/Unit)
Table 49. AstraZeneca Corporation Information
Table 50. AstraZeneca Description and Business Overview
Table 51. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. AstraZeneca Attenuated Vaccine for Human Rabies Product
Table 53. AstraZeneca Recent Developments/Updates
Table 54. GlaxoSmithKline Corporation Information
Table 55. GlaxoSmithKline Description and Business Overview
Table 56. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product
Table 58. GlaxoSmithKline Recent Developments/Updates
Table 59. Merck & Co Inc Corporation Information
Table 60. Merck & Co Inc Description and Business Overview
Table 61. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Merck & Co Inc Attenuated Vaccine for Human Rabies Product
Table 63. Merck & Co Inc Recent Developments/Updates
Table 64. Sanofi Pasteur, Inc Corporation Information
Table 65. Sanofi Pasteur, Inc Description and Business Overview
Table 66. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product
Table 68. Sanofi Pasteur, Inc Recent Developments/Updates
Table 69. Cadila Pharmaceuticals Ltd Corporation Information
Table 70. Cadila Pharmaceuticals Ltd Description and Business Overview
Table 71. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product
Table 73. Cadila Pharmaceuticals Ltd Recent Developments/Updates
Table 74. Novartis AG Corporation Information
Table 75. Novartis AG Description and Business Overview
Table 76. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Novartis AG Attenuated Vaccine for Human Rabies Product
Table 78. Novartis AG Recent Developments/Updates
Table 79. Pfizer Inc Corporation Information
Table 80. Pfizer Inc Description and Business Overview
Table 81. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Pfizer Inc Attenuated Vaccine for Human Rabies Product
Table 83. Pfizer Inc Recent Developments/Updates
Table 84. Liaoning Yisheng Biopharmaceutical Co., Ltd Corporation Information
Table 85. Liaoning Yisheng Biopharmaceutical Co., Ltd Description and Business Overview
Table 86. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 88. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 89. Lanzhou Institute of Biological Products Co., Ltd Corporation Information
Table 90. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
Table 91. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 93. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 94. Changchun Zhuoyi Biological Co., Ltd Corporation Information
Table 95. Changchun Zhuoyi Biological Co., Ltd Description and Business Overview
Table 96. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 98. Changchun Zhuoyi Biological Co., Ltd Recent Developments/Updates
Table 99. Guangzhou Nuocheng Biological Products Co., Ltd Corporation Information
Table 100. Guangzhou Nuocheng Biological Products Co., Ltd Description and Business Overview
Table 101. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 103. Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments/Updates
Table 104. Ningbo Rongan Biopharmaceutical Co., Ltd Corporation Information
Table 105. Ningbo Rongan Biopharmaceutical Co., Ltd Description and Business Overview
Table 106. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 108. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments/Updates
Table 109. Shandong Yidu Biotechnology Co., Ltd Corporation Information
Table 110. Shandong Yidu Biotechnology Co., Ltd Description and Business Overview
Table 111. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 113. Shandong Yidu Biotechnology Co., Ltd Recent Developments/Updates
Table 114. Chengdu Kanghua Biological Products Co., Ltd Corporation Information
Table 115. Chengdu Kanghua Biological Products Co., Ltd Description and Business Overview
Table 116. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 118. Chengdu Kanghua Biological Products Co., Ltd Recent Developments/Updates
Table 119. Wuhan Institute of Biological Products Co., Ltd Corporation Information
Table 120. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
Table 121. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product
Table 123. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 124. Production Base and Market Concentration Rate of Raw Material
Table 125. Key Suppliers of Raw Materials
Table 126. Attenuated Vaccine for Human Rabies Distributors List
Table 127. Attenuated Vaccine for Human Rabies Customers List
Table 128. Attenuated Vaccine for Human Rabies Market Trends
Table 129. Attenuated Vaccine for Human Rabies Market Drivers
Table 130. Attenuated Vaccine for Human Rabies Market Challenges
Table 131. Attenuated Vaccine for Human Rabies Market Restraints
Table 132. Global Attenuated Vaccine for Human Rabies Sales Forecast by Type (2023-2028) & (K Units)
Table 133. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Type (2023-2028)
Table 134. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 135. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Type (2023-2028)
Table 136. Global Attenuated Vaccine for Human Rabies Sales Forecast by Application (2023-2028) & (K Units)
Table 137. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Application (2023-2028)
Table 138. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 139. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Application (2023-2028)
Table 140. Global Attenuated Vaccine for Human Rabies Sales Forecast by Region (2023-2028) & (K Units)
Table 141. Global Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Region (2023-2028)
Table 142. Global Attenuated Vaccine for Human Rabies Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 143. Global Attenuated Vaccine for Human Rabies Revenue Market Share Forecast by Region (2023-2028)
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Attenuated Vaccine for Human Rabies
Figure 2. Global Attenuated Vaccine for Human Rabies Market Share by Type in 2021 & 2028
Figure 3. Vero Cell Product Picture
Figure 4. Human Diploid Cell Product Picture
Figure 5. Global Attenuated Vaccine for Human Rabies Market Share by Application in 2021 & 2028
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Global Attenuated Vaccine for Human Rabies Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Attenuated Vaccine for Human Rabies Market Size (2017-2028) & (US$ Million)
Figure 10. Global Attenuated Vaccine for Human Rabies Sales (2017-2028) & (K Units)
Figure 11. Attenuated Vaccine for Human Rabies Sales Share by Manufacturers in 2021
Figure 12. Global Attenuated Vaccine for Human Rabies Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Attenuated Vaccine for Human Rabies Players: Market Share by Revenue in 2021
Figure 14. Attenuated Vaccine for Human Rabies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2017-2022)
Figure 16. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region in 2021
Figure 17. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region (2017-2022)
Figure 18. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Region in 2021
Figure 19. United States Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. U.K. Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Colombia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Turkey Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Saudi Arabia Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. UAE Attenuated Vaccine for Human Rabies Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Sales Market Share of Attenuated Vaccine for Human Rabies by Type (2017-2022)
Figure 43. Manufacturing Cost Structure of Attenuated Vaccine for Human Rabies
Figure 44. Manufacturing Process Analysis of Attenuated Vaccine for Human Rabies
Figure 45. Attenuated Vaccine for Human Rabies Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
